Navigation Links
New Four Year STELARA® Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis
Date:5/25/2011

SEOUL, Korea, May 25, 2011 /PRNewswire/ -- New findings presented from pooled analyses of the STELARA® (ustekinumab) psoriasis clinical development program showed that the safety profile of STELARA and rates of adverse events remained consistent and stable over time in adults with moderate to severe plaque psoriasis receiving up to four years of treatment.  Investigators also reported findings from an analysis of four placebo-controlled Phase 3 trials across patient populations on three continents and found that the efficacy and safety of STELARA in patients of Japanese and Korean-Taiwanese descent were consistent with findings previously reported in North American and European populations.  Both sets of data were presented at the 22nd World Congress of Dermatology in Seoul, Korea.

Psoriasis, a chronic, immune-mediated disease that results from the overproduction of skin cells, affects 125 million people worldwide. Plaque psoriasis often results in patches of thick, red or inflamed skin covered with silvery scales known as plaques. These plaques usually itch or feel sore, can crack and bleed, and can occur anywhere on the body.  The disease symptoms can range from mild, to moderate, to severe and disabling.  STELARA is currently approved in 57 countries for the treatment of moderate to severe plaque psoriasis.

"These findings are promising and support a favorable benefit-to-risk profile for STELARA with up to four years of treatment," said Kristian Reich, MD, Department of Dermatology of Dermatolgikum, Hamburg, Germany, and lead trial investigator for the PHOENIX 2 study. "Ongoing studies in psoriasis and psoriatic arthritis will continue to define the safety profile of STELARA in the psoriatic population."

Pooled safety data from a total of 3,117 patients who participated in a Phase 2 STELARA trial and the Phase 3 PHOENIX 1, PHOENIX 2 and ACCEPT studies showed rates of adverse events (AEs) to be generally s
'/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Emdeon Announces Strategic Alliance with Enclarity to Address Industry Problems Created by Inconsistent Provider Data Quality
2. Innovative Psoriasis Treatment PSORENT(R) Announces Healthcare Cost Savings Potential Consistent with President Obamas Announcement on Healthcare Reform
3. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
4. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
5. MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule
6. Patient Safety Technologies Reports First Quarter 2011 Results
7. PROMUS Element™ Stent Demonstrates Exceptional Safety and Effectiveness in PLATINUM Small Vessel Study
8. Verizon Wireless and Medco Unveil First Mobile Medication App with Real-Time Patient-Specific Drug Safety and Savings Information
9. Huntsville Memorial Hospital Selects Surgical Information Systems to Increase Safety, Generate Cost Savings
10. Harvard Medical School Faculty Advances Drug Safety Research With IBM Business Analytics
11. Sacramento Police Upgrades Search and Rescue Technology with EmSeeQ® Wearable Locator System to Improve Safety for At-Risk Adults and Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)...  With all the daily obstacles facing physicians these ... keep patients healthy should be easy. Unfortunately, it isn,t ... Care Act continues to affect the way physicians are ... more important than ever that medical practices have open ... with for patient care. Each year, cloud-based ...
(Date:5/27/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/hxhwtv/asia_pacific ) has ... Market - Growth, Trends And Forecasts (2014 - 2019)" ... Asia Pacific market for Fluoroscopy ... 2014 to 2020 Fluoroscopy is the imaging ... of the interior of the body. The imaging team ...
(Date:5/27/2015)... May 27, 2015 Doctors from the ... Children,s National Health System are the first ... treat osteoid osteoma, a benign but painful bone tumor ... an experimental magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU) method. ... Niyati Shah , have been treated successfully in ...
Breaking Medicine Technology:Physicians Seek Payer Inclusion, Not Impediment 2Physicians Seek Payer Inclusion, Not Impediment 3Asia Pacific Fluoroscopy Market Trends and Forecasts 2014 - 2019 2Children's National first in US to destroy bone tumors with incisionless surgery 2Children's National first in US to destroy bone tumors with incisionless surgery 3Children's National first in US to destroy bone tumors with incisionless surgery 4
... May 5, 2011 Stereotaxis, Inc. (NASDAQ: ... entered into a new strategic collaboration with Biosense ... Solutions. This agreement marks the broadest and most ... Under the new agreement, Stereotaxis has granted ...
... 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: ... targeting the extracellular matrix , today announced that management ... Health Care Conference in Las Vegas. The presentation is scheduled ... To listen to the live webcast or a replay of ...
Cached Medicine Technology:Stereotaxis and Biosense Webster Announce New Strategic Collaboration 2Stereotaxis and Biosense Webster Announce New Strategic Collaboration 3Stereotaxis and Biosense Webster Announce New Strategic Collaboration 4Halozyme Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference on May 12 2
(Date:5/27/2015)... 2015 Continuing its commitment to finding ... in the community, SmartPractice® donated $25,000 to ... Lincoln). SmartPractice Vice President of Human Resources Meg Mosher ... $25,000 check to Paulla Miller, Sherry Gage, Dr. Linda ... Research Center on April 30. The center is located ...
(Date:5/27/2015)... Austin, Texas (PRWEB) May 27, 2015 ... margins are getting tighter, it can be challenging for ... technology for cutting edge treatments. , Austin-based ... problem, with minimally invasive, mobile medical therapies for clinically ... medical portfolio with the acquisition of Laser Ventures, ...
(Date:5/27/2015)... May 27, 2015 The new ... include: Why investors should consider oil and gas investing, ... why wells are drilled, industry news, IRA investing, definitions ... 32 years of knowledge and experience is now in ... community to be able to access 24 hours a ...
(Date:5/27/2015)... In support of a new ... the Journal of American Geriatrics Society about the link ... Bedford Commons OB-GYN P.A . is reiterating the nutritional ... , To examine the relationship between diet soda ... Longitudinal Study of Aging (SALSA) tracked the soda consumption ...
(Date:5/27/2015)... ABILENE, Texas (PRWEB) May 27, 2015 ... addition of three FDA-approved dermal filler treatments in Abilene, ... designed to reduce the appearance of glabellar lines, better ... lines. Belotero Balance® is designed to treat smoker’s ... mouth to the chin, while Radiesse® improves the appearance ...
Breaking Medicine News(10 mins):Health News:SmartPractice Donates $25,000 to HonorHealth Breast Health and Research Center 2Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 2Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 3Health News:Carson Energy Launches Next Generation Investor Website 2Health News:Recent Study About the Link Between Diet Sodas and Abdominal Fat Reinforces Bedford Commons OB-GYN's Recommendation to Drink Plenty of Water 2Health News:The MedSpa at Hendrick Introduces Xeomin®, Belotero Balance® and Radiesse® Injectables 2
... back we had carried a story about Wal-mart’s foray into ... pilot project which involved the lease of medical space in ... functioning at the Wal mart stores across 12 different states. ... World Health Care Congress, Leo Scott, the President and CEO ...
... discloses that nearly 65% of children from grade 7 to ... using artificial tanning equipments. ,The society is voicing ... under the age of 18 be prevented from tanning using ... is one of the most common forms of cancer in ...
... team of researchers at the John Hopkins Hospital in the US ... the PSA to detect prostate cancer.// ,The new test ... a simple blood test. ,Prostate cancer, the most ... of medicine. Physicians are unsure how to find it and when ...
... does not protect older women against cognitive decline, finds ... ,Identifying ways to prevent dementia is a public health ... may protect against dementia, but data from randomised studies ... US decided to test the effect of long term ...
... it is willing to proceed with the registration of a ... the Thai// government will halt its plans for a compulsory ... and will sell it to the Thai government for $1000 ... with the Thai government since January 2007, when plans for ...
... that took place last week at the Virginia Tech Many ... to formulate some// measures to avert this kind of a ... mentally ill, before they harm themselves and the others. A ... parents without the fear of infringing the privacy laws if ...
Cached Medicine News:Health News:Artificial Tanning Causes Concern 2Health News:New blood test to detect prostate cancer 2Health News:Abbott Offers Aluvia to Thailand in Return for Compulsory Licensing Halt 2Health News:Measures Needed to Avert Another Bloodbath 2
... STaK-Chex, a whole blood assayed hematology ... five-part white cell differential available with the ... unique product has 14-day open-vial stability, 105-day ... normal and high levels. The 4.0ml pierceable ...
Antelys Peek Lumbar Technologies provides a range of varied heights and angles to correct lumbar lordosis and the associated sagital balance....
Spectrum Dynamics empowers Nuclear Imaging with the SmartR Technology,of the D-SPECT Cardiac Imaging System. The D-SPECT is powered by BroadView Technology to provide unprecedented throughput, whil...
For immediate disabling...
Medicine Products: